IFPMA Clinical Trials Disclosure Code Covers All Studies Of Life-Threatening Conditions
This article was originally published in PharmAsia News
Executive Summary
The International Federation of Pharmaceutical Manufacturers & Associations' Council on Nov. 10 expanded the group's clinical trials disclosure policy to cover all clinical trials, other than exploratory trials
You may also be interested in...
International Pharma Associations Lay Principles For Publishing Trial Data, Regardless Of Outcome
HONG KONG - Multinational pharmaceutical companies may start submitting for publication the results of more clinical trials, whether they are successful or not, as part of a new set of principles endorsed by industry associations around the world
International Pharma Associations Lay Principles For Publishing Trial Data, Regardless Of Outcome
HONG KONG - Multinational pharmaceutical companies may start submitting for publication the results of more clinical trials, whether they are successful or not, as part of a new set of principles endorsed by industry associations around the world
PhRMA Clinical Trial Code: Disclosure Edition
PhRMA is using broad disclosure as a defense against questions of clinical trial bias. Disclosure used to be a penalty forced on firms in consent decrees and lawsuits; now it appears as a pillar to building trust for corporate-sponsored trials.